Skip to main content
MedPathMedPath Home
Clinical Trials/EUCTR2005-000699-41-IT
EUCTR2005-000699-41-IT
Active, Not Recruiting
N/A

Multicentric Pilot Phase II Study for use of Fludarabine plus Cyclophosphamide Followed by 90 Y-Ibritumomab Tiuxetan Zevalin in the Treatment of non-Follicular Indolent Lymphomas Refractory or Relapsed after Conventional Front-Line Chemotherapy not Containing Fludarabine

AZIENDA OSPEDALIERA OSPEDALI RIUNITI DI BERGAMO A.O. DI RILIEVO NAZIONALE0 sites80 target enrollmentFebruary 1, 2007
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsTreatment patients with non-Follicular Indolent Lymphomas Refractory or Relapsed after Conventional Front-Line Chemotherapy not Containing Fludarabine and Ciclofosfamide
DrugsFLUDARA*15CPR RIV 10MGMABTHERA*EV 1FL 50ML 500MG

Overview

Phase
N/A
Intervention
Not specified
Conditions
Treatment patients with non-Follicular Indolent Lymphomas Refractory or Relapsed after Conventional Front-Line Chemotherapy not Containing Fludarabine and Ciclofosfamide
Sponsor
AZIENDA OSPEDALIERA OSPEDALI RIUNITI DI BERGAMO A.O. DI RILIEVO NAZIONALE
Enrollment
80
Status
Active, Not Recruiting
Last Updated
14 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
February 1, 2007
End Date
TBD
Last Updated
14 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
AZIENDA OSPEDALIERA OSPEDALI RIUNITI DI BERGAMO A.O. DI RILIEVO NAZIONALE

Eligibility Criteria

Inclusion Criteria

  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1\.2 Adults (18\-64 years) yes
  • •F.1\.2\.1 Number of subjects for this age range
  • •F.1\.3 Elderly (\>\=65 years) yes
  • •F.1\.3\.1 Number of subjects for this age range

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Phase 2
Study of addition of fludarabine to the standard regimen of Anti-thymocyte globulin (ATG) and cyclosporine in patients with aplastic anemia (condition that occurs when the body stops producing enough new blood cells)Health Condition 1: null- PATIENTS WITH APLASIC ANEMIA
CTRI/2014/06/004676INVESTIGATOR INITIATED STUDY20
Active, Not Recruiting
Phase 2
High powered ultrasound to treat pancreas cancerocally advanced pancreatic cancerCancerMalignant neoplasm of pancreas
ISRCTN56087634niversity of Oxford20
Active, Not Recruiting
Phase 1
A study evaluating the safety and efficacy of 19CP02 in subjects with non-Hodgkin lymphomaRelapsed/refractory B-cell non-Hodgkin lymphomaMedDRA version: 20.0Level: HLGTClassification code 10025320Term: Lymphomas non-Hodgkin's B-cellSystem Organ Class: 10005329 - Blood and lymphatic system disordersTherapeutic area: Diseases [C] - Cancer [C04]
EUCTR2021-003272-13-NLCellPoint B.V.45
Active, Not Recruiting
Phase 1
A study evaluating the safety and efficacy of 19CP02 in subjects with non-Hodgkin lymphoma
EUCTR2021-003272-13-BECellPoint B.V.45
Active, Not Recruiting
Phase 1
A study evaluating the safety and efficacy of GLPG5101 (19CP02) in subjects with non-Hodgkin lymphoma
CTIS2022-502661-23-00Galapagos40